Serum linc<scp>RNA</scp>‐p21 as a potential biomarker of liver fibrosis in chronic hepatitis B patients

Yu, Fang; Zhou, Guangyao; Huang, Kate; Fan, XuFei; Li, Guojun; Chen, Bicheng; Dong, Peihong; Zheng, Jianjian

doi:10.1111/jvh.12680

Cited by 28 publications

(37 citation statements)

References 38 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum levels of lncRNA-p21 were negatively correlated with liver fibrosis in HBV patients [117]. Yu et al [68] determined that lncRNA-p21 enhanced the expression of PTEN by sequestering miR-181b as a ceRNA and inhibited HSC activation through the PTEN/Akt pathway in liver fibrosis [68].…”

Section: Lncrnap21mentioning

confidence: 99%

LncRNAs Act as a Link between Chronic Liver Disease and Hepatocellular Carcinoma

Kim

Park

Lee

2020

IJMS

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are emerging as important contributors to the biological processes underlying the pathophysiology of various human diseases, including hepatocellular carcinoma (HCC). However, the involvement of these molecules in chronic liver diseases, such as nonalcoholic fatty liver disease (NAFLD) and viral hepatitis, has only recently been considered in scientific research. While extensive studies on the pathogenesis of the development of HCC from hepatic fibrosis have been conducted, their regulatory molecular mechanisms are still only partially understood. The underlying mechanisms related to lncRNAs leading to HCC from chronic liver diseases and cirrhosis have not yet been entirely elucidated. Therefore, elucidating the functional roles of lncRNAs in chronic liver disease and HCC can contribute to a better understanding of the molecular mechanisms, and may help in developing novel diagnostic biomarkers and therapeutic targets for HCC, as well as in preventing the progression of chronic liver disease to HCC. Here, we comprehensively review and briefly summarize some lncRNAs that participate in both hepatic fibrosis and HCC.

show abstract

Section: Lncrnap21mentioning

confidence: 99%

LncRNAs Act as a Link between Chronic Liver Disease and Hepatocellular Carcinoma

Kim

Park

Lee

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Long noncoding RNAs (lncRNAs) are non-protein-coding RNAs that lack an open reading frame [5]. Recently, studies have found that lncRNAs are involved in various cellular functions through different mechanisms such as posttranscriptional, transcriptional [6][7][8]. Zhang et al revealed that lncRNA LINC00305 promotes inflammation through activation of the aryl hydrocarbon receptor repressor (AHRR)-nuclear factor nuclear factor-kB (NF-κB) pathway [9].…”

Section: Introductionmentioning

confidence: 99%

The role of the LncRNA-FA2H-2-MLKL pathway in atherosclerosis by regulation of autophagy flux and inflammation through mTOR-dependent signaling

et al. 2019

View full text Add to dashboard Cite

Atherosclerosis is a progressive, chronic inflammation in arterial walls. Long noncoding RNAs (lncRNAs) participate in inflammation, but the exact mechanism in atherosclerosis is unclear. Our microarray analyses revealed that the levels of lncRNA-FA2H-2 were significantly decreased by oxidized low-density lipoprotein (OX-LDL). Bioinformatics analyses indicated that mixed lineage kinase domain-like protein (MLKL) might be regulated by lncRNA-FA2H-2. In vitro experiments showed that lncRNA-FA2H-2 interacted with the promoter of the MLKL gene, downregulated MLKL expression, and the binding sites between −750 and 471 were necessary for lncRNA-FA2H-2 responsiveness to MLKL. Silencing lncRNA-FA2H-2 and overexpression of MLKL could activate inflammation and inhibited autophagy flux. Both lncRNA-FA2H-2 knockdown and overexpression of MLKL could significantly aggravate inflammatory responses induced by OX-LDL. We found that the 3-methyladenine (3-MA) and Atg7-shRNA enhanced inflammatory responses induced by knockdown of lncRNA-FA2H-2 and overexpression of MLKL. We demonstrated that the effects of MLKL on autophagy might be associated with a mechanistic target of rapamycin (mTOR)-dependent signaling pathways. In vivo experiments with apoE knockout mice fed a western diet demonstrated that LncRNA-FA2H-2 knockdown decreased microtubuleassociated expression of microtubule-associated protein 1 light chain 3 II and lysosome-associated membrane protein 1, but increased expression of sequestosome 1 (p62), MLKL, vascular cell adhesion molecule-1, monocyte chemoattractant protein-1, and interleukin-6 in atherosclerotic lesions. Our findings indicated that the lncRNA-FA2H-2-MLKL pathway is essential for regulation of autophagy and inflammation, and suggested that lncRNA-FA2H-2 and MLKL could act as potential therapeutic targets to ameliorate atherosclerosis-related diseases.

show abstract

“…LncRNAs induced by HCV infection may regulate the expression of coding genes required for the replication of the virus or regulation of genes involved in the cellular antiviral response 33 . The expression levels of the lncRNA maternally expressed gene 3 (MEG3) 34 and the lincRNA p21 35 have been found to be reduced during liver fibrosis and, thus, may potentially serve as biomarkers of fibrosis. The lncRNA growth arrest-specific transcript 5 (GAS5) inhibits HCV replication 36 and participates in the activation and proliferation of HSCs 37 .…”

Section: Discussionmentioning

confidence: 99%

RNA Profiling Analysis of the Serum Exosomes Derived from Patients with Chronic Hepatitis and Acute-on-chronic Liver Failure Caused By HBV

Chen

Zhang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Hepatitis B virus (HBV) is the main causative viral agent for liver diseases in China.In liver injury, exosomes may impede the interaction with chromatin in the target cell and transmit inflammatory, apoptosis, or regeneration signals through RNAs. Therefore, we attempted to determine the potential functions of exosomal RNAs using bioinformatics technology. We performed RNA sequencing analysis in exosomes derived from clinical specimens of healthy control (HC) individuals and patients with chronic hepatitis B (CHB) and acute-on-chronic liver failure caused by HBV (HBV-ACLF). This analysis resulted in the identification of different types and proportions of RNAs in exosomes from the HC individuals and patients. Exosomes from the CHB and HBV-ACLF patients showed distinct upregulation and downregulation patterns of differentially expressed genes compared with those from the HC subjects. Gene Ontology and Kyoto Encyclopaedia of Genes and Genomes pathway analysis further confirmed different patterns of biological functions and signalling pathways in CHB and HBV-ACLF. Then we chose two upregulated RNAs both in CHB and HBV-ACLF for further qPCR validation. It confirmed the significantly different expression levels in CHB and HBV-ACLF compared with HC. Our findings indicate selective packaging of the RNA cargo into exosomes under different HBV attacks; these may represent potential targets for the diagnosis and treatment of HBV-caused liver injury.Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. The World Health Organisation estimates that, globally, 257 million people are living with hepatitis B virus (HBV) infection, which resulted in 887,000 deaths in 2015 1 . Chronic hepatitis B (CHB) includes three phases, i.e. immune-tolerant, immune-active, and inactive phases 2 . In the immune-active phase, various degrees of necroinflammation, with or without fibrosis, are observed in the liver 3 . Hepatitis flares can be controlled with antiviral therapy, but liver failure is a significant cause of overall morbidity, even with antiviral drugs 4 .The median mortality rate associated with acute-on-chronic liver failure (ACLF) has been reported to range from 50% to 90% 5 , which is different from that with hepatitis flares. In China, the plasma exchange-centred artificial liver support system has improved the prognosis of HBV-caused ACLF (HBV-ACLF), but the 1-month mortality rate remains high at 38.4% 4 . A better understanding of the molecular mechanisms of the development and progression of immune-active CHB and HBV-ACLF may allow a more accurate prediction of their outcomes and the optimisation of therapeutic regimens. Therefore, reliable and effective diagnosis and treatment strategies are urgently needed.Exosomes are spheroidal particles with a lipid bilayer membrane, containing various classes of nucleic acids, proteins, and lipids 6 . Exosomes have been recognised as universal intercellular communication vesicles released by cells and able to horizontally transfer biochem...

show abstract

Serum lincRNA‐p21 as a potential biomarker of liver fibrosis in chronic hepatitis B patients

Cited by 28 publications

References 38 publications

LncRNAs Act as a Link between Chronic Liver Disease and Hepatocellular Carcinoma

LncRNAs Act as a Link between Chronic Liver Disease and Hepatocellular Carcinoma

The role of the LncRNA-FA2H-2-MLKL pathway in atherosclerosis by regulation of autophagy flux and inflammation through mTOR-dependent signaling

RNA Profiling Analysis of the Serum Exosomes Derived from Patients with Chronic Hepatitis and Acute-on-chronic Liver Failure Caused By HBV

Contact Info

Product

Resources

About